SCHEMBL8313102

SCHEMBL8313102

CNc1nccc2ccc(C)cc12

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.42
CCR5 P51681 1/20 0.42
CCR8 P51685 1/20 0.42
CYP2A6 P11509 4/20 0.41
CYP1A2 P05177 3/20 0.41
IKBKB O14920 2/20 0.41
HTR1A P08908 3/20 0.40
ADRA1D P25100 3/20 0.40
ADRA1A P35348 3/20 0.40
ADRA1B P35368 3/20 0.40
HDAC3 O15379 5/20 0.40
HDAC1 Q13547 5/20 0.40
HDAC6 Q9UBN7 5/20 0.40
ALDH1A1 P00352 1/20 0.39
UHRF1 Q96T88 1/20 0.38
AURKA O14965 1/20 0.36
METAP2 P50579 1/20 0.36
METAP1 P53582 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8297790 0.85 WNT3A (0.41) CCR1CCR5CCR8CYP2A6CYP1A2
SCHEMBL11843754 0.84 CCR1 (0.41) CCR1CCR5CCR8CYP2A6CYP1A2
SCHEMBL509135 0.81 EGFR (0.42) HDAC3HDAC1HDAC6
SCHEMBL24151604 0.80 PLAU (0.47) CYP1A2HDAC3HDAC1HDAC6ALDH1A1
SCHEMBL16455340 0.80 CTDSP1 (0.38) HTR1AALDH1A1
SCHEMBL27051340 0.80 TNF (0.46) ALDH1A1METAP2METAP1
SCHEMBL30727448 0.80 TNF (0.46) ALDH1A1METAP2METAP1
SCHEMBL8404535 0.76 CYP2A6 (0.57) CCR1CCR5CCR8CYP2A6CYP1A2
SCHEMBL2671305 0.75 PLAU (0.55) HDAC3HDAC1HDAC6ALDH1A1
SCHEMBL4479184 0.75 CYP2A6 (0.55) CYP2A6CYP1A2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090062267-A1 L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS ASTRAZENECA AB (SE) 2009-03-05 US disclosed
US-20080182842-A1 L-alanine derivatives as a5beta1 antagonists ASTRAZENECA AB (SE) 2008-07-31 US disclosed
WO-2004072102-A2 BENZENE ACETAMIDE COMPOUNDS USEFUL AS SERINE PROTEASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-08-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062267-A1 L-ALANINE DERIVATIVES AS a5beta1 ANTAGONISTS ITGA2B, ITGB1, ITGAL CCR1 1560/4885CCR5 826/4885CCR8 3135/4885
US-20080182842-A1 L-alanine derivatives as a5beta1 antagonists ITGB1, ITGA2B, ITGB5 CCR1 1340/4885CCR5 762/4885CCR8 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.